{"organizations": [], "uuid": "69e987aff0314da63911062987be5d7c6d7f589d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/idUSL8N1P30UN", "country": "US", "domain_rank": 408, "title": "BRIEF-Sanofi And Alnylam Pharmaceuticals Enter Into Partnership", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-08T09:23:00.000+02:00", "replies_count": 0, "uuid": "69e987aff0314da63911062987be5d7c6d7f589d"}, "author": "", "url": "https://www.reuters.com/article/idUSL8N1P30UN", "ord_in_thread": 0, "title": "BRIEF-Sanofi And Alnylam Pharmaceuticals Enter Into Partnership", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "alnylam pharmaceuticals enter into partnership reute", "sentiment": "negative"}, {"name": "alnylam pharmaceuticals enter into partnership", "sentiment": "negative"}, {"name": "sanofi genzyme", "sentiment": "none"}, {"name": "sanofi", "sentiment": "none"}, {"name": "alnylam", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 8, 2018 / 7:25 AM / Updated 2 hours ago BRIEF-Sanofi And Alnylam Pharmaceuticals Enter Into Partnership Reuters Staff \nJan 8 (Reuters) - SANOFI SA: \n* AND ALNYLAM, ANNOUNCED ON SUNDAY STRATEGIC RESTRUCTURING OF RNAI THERAPEUTICS RARE DISEASE ALLIANCE \n* SANOFI WILL OBTAIN GLOBAL DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO FITUSIRAN \n* GLOBAL COMMERCIALIZATION OF FITUSIRAN, UPON APPROVAL, WILL BE DONE BY SANOFI GENZYME \n* ALNYLAM WILL RECEIVE ROYALTIES BASED ON NET SALES OF FITUSIRAN PRODUCTS \n* ALNYLAM TO OBTAIN GLOBAL DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO ITS INVESTIGATIONAL RNAI THERAPEUTICS PROGRAMS FOR THE TREATMENT OF ATTR AMYLOIDOSIS, INCLUDING PATISIRAN AND ALN-TTRSC02 \n* SANOFI WILL RECEIVE ROYALTIES BASED ON NET SALES OF THESE ATTR AMYLOIDOSIS PRODUCTS \nSource text for Eikon:", "external_links": [], "published": "2018-01-08T09:23:00.000+02:00", "crawled": "2018-01-08T09:34:20.062+02:00", "highlightTitle": ""}